Navigation Links
MediPurpose Sells 500 Millionth Safety Lancet to IMCO Member MMS Medical

NORCROSS, Ga., Feb. 1 /PRNewswire/ -- MediPurpose, an innovator in the medical device industry, has passed the 500 million mark for its industry- leading SurgiLance safety lancet. In recognition of this significant milestone, the company will hold a brief ceremony on Thursday, Feb. 21, at the offices of MMS Medical of St. Louis, Mo., the distributor who purchased the 500 millionth lancet.

"We want all our customers to share in this significant achievement and to know how much they are valued by the MediPurpose team. We are committed to continued innovation in healthcare." says CEO Patrick Yi.

Introduced in 2000, the SurgiLance safety lancet has found long-term success in all sectors of the healthcare market and has provided more than 500 million consumers with a safe, simple and effective tool for blood testing. MediPurpose currently offers six color-coded lancets, which are used for capillary blood sampling for a range of testing requirements.

To help the millions of children living with diabetes, MediPurpose will make a $1,000 donation to the Juvenile Diabetes Research Foundation in the name of MMS Medical. Chuck Berry, Walgreens District Manager, will accept the donation for JDRF. Berry is president of board for the Metro St. Louis / Greater Missouri chapter of JDRF. MMS Medical is a member of Independent Medical Co-Op (IMCO), a leading cooperative for medical supply distributors

"We are pleased that one of our members, MMS Medical, is being recognized by MediPurpose, a long-time valued supplier," says Deb Bullock, Vice President for IMCO. "We extend our congratulations to MediPurpose and its SurgiLance safety lancet on this significant achievement and look forward to continued growth together."

"We consider distributors like MMS Medical to be full partners in our success," says Randy Prather, MediPurpose VP of Sales and Marketing. "Since early 2001, MediPurpose has maintained a strong and vibrant relationship with IMCO and its member companies. They have grown into one of our most valued distribution partners." MMS Medical has purchased SurgiLance safety lancets since 2002.

"On behalf of MMS, we would like to congratulate MediPurpose on this sales milestone," says Kelly Hart, MMS Vice President Long Term Care. "We are honored to be a part of the celebration and look forward to our continued partnership to help improve the lives of those with diabetes."

About MediPurpose

MediPurpose develops, manufactures and markets innovative healthcare solutions valued by its customers. The company is known for introducing quality safety medical devices that protect healthcare professionals from sharps injury. Founded in 1999, the company achieved rapid success with its SurgiLance safety lancet, quickly becoming one of the top leaders in the US safety lancet market and establishing solid distribution channels worldwide.

MediPurpose maintains offices in the US, Singapore, the UK, France and Spain. As a globally recognized innovator, MediPurpose has developed a menu of services to assist inventors and growing medical device companies successfully design, patent, manufacture and sell their products.

For more information on MediPurpose, visit

SOURCE MediPurpose
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. TeamStaff Sells Per Diem Business Unit
2. Turnaround Partners Sells Minority Ownership in Interactive Nutrition to Natural Nutrition
3. Informed Medical Communications Sells Consumer Internet Division to Revolution Health
4. Dragon Sells EPO Business; Focus on Antibiotic Core Business
5. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
6. Celebrity Seating Only! Levitz Chair Signed by 39 Daytime Stars Sells for $1200 on
7. OSHA Seeking Nominations for National Advisory Committee on Occupational Safety and Health
8. Using the safety belt in the rear seats of the car reduces death risk by almost a half
9. The American Society for Aesthetic Plastic Surgery Addresses the Safety of Botox
10. The Great Safety Adventure(R) Traveling Home Safety Exhibit Kicks Off Tenth Anniversary Tour
11. Debate over safety of gene therapy trials focuses on issue of informed consent
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology: